AbbVie Inc.
ABBV · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $56,334,000 | $54,318,000 | $58,054,000 | $56,197,000 |
| % Growth | 3.7% | -6.4% | 3.3% | – |
| Cost of Goods Sold | $16,904,000 | $20,415,000 | $17,414,000 | $17,446,000 |
| Gross Profit | $39,430,000 | $33,903,000 | $40,640,000 | $38,751,000 |
| % Margin | 70% | 62.4% | 70% | 69% |
| R&D Expenses | $12,791,000 | $7,675,000 | $6,510,000 | $8,046,000 |
| G&A Expenses | $11,089,000 | $10,704,000 | $13,260,000 | $10,249,000 |
| SG&A Expenses | $13,189,000 | $12,872,000 | $15,260,000 | $12,349,000 |
| Sales & Mktg Exp. | $2,100,000 | $2,200,000 | $2,000,000 | $2,100,000 |
| Other Operating Expenses | $4,313,000 | $599,000 | $753,000 | $432,000 |
| Operating Expenses | $30,293,000 | $21,146,000 | $22,523,000 | $20,827,000 |
| Operating Income | $9,137,000 | $12,757,000 | $18,117,000 | $17,924,000 |
| % Margin | 16.2% | 23.5% | 31.2% | 31.9% |
| Other Income/Exp. Net | -$5,421,000 | -$6,507,000 | -$4,640,000 | -$4,935,000 |
| Pre-Tax Income | $3,716,000 | $6,250,000 | $13,477,000 | $12,989,000 |
| Tax Expense | -$570,000 | $1,377,000 | $1,632,000 | $1,440,000 |
| Net Income | $4,278,000 | $4,863,000 | $11,836,000 | $11,542,000 |
| % Margin | 7.6% | 9% | 20.4% | 20.5% |
| EPS | 2.4 | 2.73 | 6.65 | 6.48 |
| % Growth | -12.1% | -58.9% | 2.6% | – |
| EPS Diluted | 2.39 | 2.72 | 6.63 | 6.45 |
| Weighted Avg Shares Out | 1,769,000 | 1,768,000 | 1,771,000 | 1,770,000 |
| Weighted Avg Shares Out Dil | 1,773,000 | 1,773,000 | 1,778,000 | 1,777,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $648,000 | $540,000 | $186,000 | $39,000 |
| Interest Expense | $2,808,000 | $2,224,000 | $2,230,000 | $2,423,000 |
| Depreciation & Amortization | $8,386,000 | $8,698,000 | $8,467,000 | $8,521,000 |
| EBITDA | $14,910,000 | $17,172,000 | $24,174,000 | $23,933,000 |
| % Margin | 26.5% | 31.6% | 41.6% | 42.6% |